Alnylam announces results from ALN-VSP Phase I study on liver cancers

[News]

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced results today from its Phase I extension study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

More... (http://www.news-medical.net/news/20120605/Alnylam-announces-results-from-ALN-VSP-Phase-I-study-on-liver-cancers.aspx)